Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.

  title={Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.},
  author={Jun Gang Zhou and Kathleen M. Mahoney and Anita Giobbie-Hurder and Fengmin Zhao and Sandra J. Lee and Xiaoyun Liao and Scott J Rodig and Jingjing Li and Xinqi Wu and Lisa H Butterfield and Matthias Piesche and Michael P Manos and Lauren M. Eastman and Glenn Dranoff and Gordon J Freeman and Frank Stephen Hodi},
  journal={Cancer immunology research},
  volume={5 6},
Blockade of the pathway including programmed death-ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) has produced clinical benefits in patients with a variety of cancers. Elevated levels of soluble PD-L1 (sPD-L1) have been associated with worse prognosis in renal cell carcinoma and multiple myeloma. However, the regulatory roles and function of sPD-L1 particularly in connection with immune checkpoint blockade treatment are not fully understood. We identified four splice… CONTINUE READING
Highly Cited
This paper has 26 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 15 extracted citations


Publications referenced by this paper.
Showing 1-10 of 47 references

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas Cancer

  • BJ Chen, B Chapuy, J Ouyang, HH Sun, MG Roemer, ML Xu
  • Immunol Res;
  • 2017
1 Excerpt

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

  • D Rossille, GressierM, DamotteD, Maucort-BoulchD, C Pangault, G Semana
  • Leukemia
  • 2014

Similar Papers

Loading similar papers…